STING1 and cervical carcinoma: STING activation has also been shown to increase PD-L1 expression in cervical cancer cells through the NF-κB pathway, which could be clinically meaningful if this translated into improved immune evasion, and would suggest a benefit for pharmaceuticals targeting the STING pathway to be given with PD-L1 inhibitors (Cai et al., 2020).